Martin R M, Kerry S M, Hilton S R
Division of General Practice and Primary Care, 6th Floor, Hunter Wing, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK.
Pharmacoepidemiol Drug Saf. 1997 Jul;6(4):253-61. doi: 10.1002/(SICI)1099-1557(199707)6:4<253::AID-PDS284>3.0.CO;2-5.
Information on general practitioners' choices of initial and second-line antihypertensive treatment, and reasons for stopping therapy, are limited. We analysed data on the use of the four main classes of antihypertensive drugs (diuretics, beta-blockers, calcium antagonists and angiotensin-converting enzyme inhibitors) between 1990 and 1995 from an ongoing cross-sectional postal survey of general practitioners' prescribing activity (the New and Change Therapy Enquiry). There were 18,092 new courses and 9424 discontinuations between 1990 and 1995. Diuretics were the commonest first-line choice. Use of beta-blockers first-line decreased significantly in comparison with diuretics during the study period. Switches to calcium antagonists and angiotensin-converting enzyme inhibitors increased. The increased use of newer agents was not explained by increased use for concomitant conditions (diabetes or cardiovascular disease). Diuretics were most often discontinued because of poor efficacy (44% of diuretic stops). In contrast, most beta-blockers (55%), calcium antagonists (64%) and angiotensin-converting enzyme inhibitors (60%) were stopped because of side-effects. In conclusion, use of beta-blockers first-line decreased. Switches to calcium antagonists and angiotensin-converting enzyme inhibitors increased. The reasons may be due to greater perceived efficacy of newer agents rather than increased use for concomitant conditions.
关于全科医生对一线和二线降压治疗的选择以及停药原因的信息有限。我们分析了1990年至1995年间正在进行的全科医生处方活动横断面邮政调查(新疗法与变更疗法调查)中四类主要降压药物(利尿剂、β受体阻滞剂、钙拮抗剂和血管紧张素转换酶抑制剂)的使用数据。1990年至1995年间有18092个新疗程和9424次停药情况。利尿剂是最常见的一线选择。在研究期间,与利尿剂相比,一线使用β受体阻滞剂的情况显著减少。转而使用钙拮抗剂和血管紧张素转换酶抑制剂的情况增加。新型药物使用增加并非因合并症(糖尿病或心血管疾病)使用增加所致。利尿剂最常因疗效不佳而停药(利尿剂停药情况的44%)。相比之下,大多数β受体阻滞剂(55%)、钙拮抗剂(64%)和血管紧张素转换酶抑制剂(60%)因副作用而停药。总之,一线使用β受体阻滞剂的情况减少。转而使用钙拮抗剂和血管紧张素转换酶抑制剂的情况增加。原因可能是新型药物被认为疗效更佳,而非合并症使用增加。